HDAC inhibitors are new and emerging cancer therapies; however, few studies have focused on the TME as an endpoint for their activity.35 We show that Scriptaid antagonises TGFβ-mediated CAF gene expression, which accompanies diminished ECM deposition, reduced contractility, and ECM stiffness, and delayed tumour growth in vivo; thus, Scriptaid potentially reverses a tumour-permissive microenvironment by reducing ECM accumulation preventing activation of intrinsic mechanosensory pathways in CAFs and cancer cells that promote cancer progression. This evidence concerns the gene HDAC9 and neoplasm.